MARKETS / US / RLFTY

US · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Relief Therapeutics Holding SA RLFTY

3 fiscal years on record · CHF · FY2023 reported

SEC FILINGS ONLY

Revenue · FY2023

CHF 6.3M

▼ 11.0% vs FY2022

EPS · FY23

CHF -8.35

Dividend / sh · FY23

—

Payout · FY23

—

ROE · FY23

—

Net margin · FY23

-1551.5%

Dividend coverage

—

Result

CHF 6.3M

Revenue, FY2023 · full 3-year series below

Revenue Net income

The company lost 1552 cents on every revenue dollar this year.

Per share

CHF -8.35

Diluted EPS, FY2023

EPS

The company pays no cash dividend.

Profitability

—

Return on equity, FY2023

ROE

Operating margin-1751.4%

Net margin-1551.5%

Return on assets-74.0%

Returned to shareholders

—

returned in FY2023 · dividends + net buybacks

Dividends paid—

Net buybacks—

Share of profit—

Consecutive raises—

Growth

—

revenue, compounded over five years

CAGR

3 yrs

5 yrs

10 yrs

15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base

—

Shares outstanding, FY2023

Change, 5 years—

Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Balance sheet

CHF 76.4M

total assets, end of FY2023

Total assetsCHF 76.4M

CashCHF 14.6M

Current ratio2.65×

History

3 fiscal years

Every figure from documents filed with the SEC · CHF

Metric

2023

2022

2021

Revenue CHF B

0.0

Operating income CHF B

−0.1

−0.0

EBITDA CHF B

−0.1

−0.0

Income tax CHF B

−0.0

Net income CHF B

−0.1

−0.0

EPS, diluted CHF

−8.35

−4.80

−0.01

Dividend / sh CHF

Payout %

ROE %

Shares out B

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED

9 of 9

checks passed before publication

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed

Market capitalizationneeds a market quote — not yet licensed

Dividend yieldneeds a market quote — not yet licensed

Price-to-bookneeds a market quote — not yet licensed